ADGSOM1 & ADGMIN1  
       
  LAUNCH OF THE 50TH ANNIVERSARY CELEBRATION OF RUKUN NEGARA  
       
  KL SUMMIT 2019  
       
  HAWANA 2018  
       
  AES 2016  
       

 
 
 

May 28, 2024 -Tuesday

 
  GALDERMA ANNOUNCES EXPANSION PLANS TO BETTER SERVE HEALTHCARE PROFESSIONALS AND INSTITUTIONS IN MALAYSIA

Friday 31/03/2023



KUALA LUMPUR, Malaysia, March 31 (Bernama-PRNewswire) -- Galderma, the pure-play dermatology company, announces a change in its marketing operations to better serve the healthcare community in Malaysia. Through this development, the company has established its own team of marketing personnel, product specialists and brand representatives to engage with healthcare professionals and institutions directly. The transfer of commercial activities (sales and marketing) of the company from Zuellig Pharma Sdn Bhd has taken effect since January 2023. 

"Our goal is to continue supporting our strong growth trajectory with an enhanced focus that will significantly increase our ability to engage and better serve our healthcare community. This year, Galderma will be focusing on broadening engagement sessions with healthcare professionals that are thought leadership in nature and is backed with dermatology science. This expansion plan is in line with the company's business strategy to consistently expand its synergistic portfolio of flagship brands, supported by science-based product differentiation and premium positioning to match consumer and patient needs with superior outcomes. At Galderma, we understand that our skin shapes our lives. We are advancing dermatology for every skin story."
CINDY TIU
COUNTRY MANAGER, GALDERMA MALAYSIA

Galderma Malaysia provides a comprehensive product portfolio including Cetaphil® (Malaysia's #1 dermatological skincare brand), Epiduo®, Differin®, Restylane®, Sculptra®, Tri-Luma®, Benzac®, Retacnyl®, Rozex®, Loceryl®, Clobex®. The announcement of this expansion comes as part of Galderma's next phase of growth for Malaysia.

In 2022, Galderma delivered strong performance globally with 13.9% year-on-year net sales growth on a constant currency basis, driven by innovation and commercial performance. The sustained growth momentum was fueled by continued strong performance in Injectable Aesthetics and Dermatological Skincare[1].

Galderma delivers an innovative, science-based portfolio of premium flagship brands and services that spans the full spectrum of the fast-growing dermatology market. Galderma's unique portfolio of anti-acne products is the number one choice worldwide[2]. Additionally, Galderma is known for its diverse portfolio of injectable technologies with over two decades of aesthetic innovation and experience from over 85 million treatments worldwide. Cutting-edge innovation is also at the core of Galderma's Dermatological Skincare product category, with clinical data showing that Cetaphil's formula defends against 5 signs of skin sensitivity (dryness, roughness, irritation, tightness and weakened skin barrier) and helps restore and rebuild the skin moisture barrier.

For more information: www.galderma.com
 
[1] Galderma. Galderma delivers strong FY 2022 growth driven by innovation and commercial performance. 13 March 2023.
 
[2] Based on internal analysis by Galderma using data from the following source: IQVIA: MIDAS® Global Quarterly, Q2 2022, ATC: D10 ANTI-ACNE PREPARATIONS, 75 countries, for the time period MAT Q2 2022 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved. 


CONTACT: Jessica Chan (jessica.chan@galderma.com)

SOURCE : CETAPHIL

--BERNAMA
 

 
 
 

Copyright © 2024 MREM . All rights reserved.